Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224029 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition
A Phase 4 study of Detrusor Hyperreflexia, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 6
- Study locations
NCT00224029: Completed Phase 4 study of Detrusor Hyperreflexia, sponsored by Watson Pharmaceuticals.
NCT00224029 is a Phase 4 study of Detrusor Hyperreflexia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00224029, a Phase 4 study of Detrusor Hyperreflexia, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
Primary Outcome
Baseline in number of daily catheterizations without leaking per day as recorded in a 3-day urinary diary.
Conditions Studied
Interventions
- DRUG Oxybutynin transdermal system
Study Locations (6)
North Carolina
- - Chapel Hill
- - Charlotte
Texas
- - Dallas
- - Houston
Georgia
- - Atlanta
New York
- - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-05 |
| Phase | Phase 4 |
What the finished NCT00224029 record still lists
NCT00224029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Detrusor Hyperreflexia appearing as the primary indexed condition, and to 1 intervention - of which Oxybutynin transdermal system is the first listed.
NCT00224029 lists 6 locations in 4 states (North Carolina, Texas, Georgia).
Frequently Asked Questions
What is clinical trial NCT00224029 about?
NCT00224029 is a clinical study titled "A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition". This study will evaluate the efficacy and safety of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in adults who have spinal cord injury.
What is the current status of trial NCT00224029?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2004-12. Estimated completion is 2008-05.
What conditions does trial NCT00224029 study?
This clinical trial studies the following conditions: Detrusor Hyperreflexia.
What interventions are being tested in trial NCT00224029?
The interventions under investigation include: Oxybutynin transdermal system (DRUG).
Who is sponsoring clinical trial NCT00224029?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224029 being conducted?
This trial has 6 study locations across Georgia, New York, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Detrusor Hyperreflexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00224029's enrollment target sits among peer trials
24 1699th of 2000 higher than 277 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia